Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation
Ibiayi Dagogo‐Jack(Massachusetts General Hospital)
Cited by 28
Related Papers
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
|Clinical Cancer Research|2021|137
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
|Journal of Thoracic Oncology|2018|82